A Clinical Study of MK-4082 in Healthy Overweight Participants (MK-4082-002)

Part of paid clinical trials in Anaheim, California.

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT07388667
Phase
PHASE1
Status
Active Not Recruiting

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Accepted

Interventions

  • MK-4082 — DRUG
    Oral Tablet
  • Placebo — DRUG
    Oral Tablet

Study Details

Researchers are looking for new weight loss medicines for people with higher body weight. The study medicine, MK-4082, is different from similar weight loss medicines because people take it as a pill instead of an injection. Before giving a study medicine to people with a health condition, researchers first do studies to find a safe dose level (amount) of the study medicine that can be used in future studies. The goals of this study are to learn about: * The safety of MK-4082 and if people tolerate it * What happens to different MK-4082 dose levels in a person's body over time

Key Dates

Start date
Mar 4, 2026
Status verified
Jun 2026
Primary completion
Sep 2, 2026
Completion
Sep 9, 2026

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Panel A: Dose Escalation to Dosage 1
    Participants receive escalating doses of oral MK-4082 once daily (QD) or a dose-matched placebo to reach maintenance dose 1.
  • Experimental: Panel B: Dose Escalation to Dosage 2
    Participants receive escalating doses of oral MK-4082 QD or a dose-matched placebo to reach maintenance dose 2.
  • Experimental: Panel C: Dose Escalation to Dosage 3
    Participants receive escalating doses of oral MK-4082 once daily (QD) or a dose-matched placebo to reach maintenance dose 3.
  • Experimental: Panel D: Dose Escalation to Dosage 4
    Participants receive escalating doses of oral MK-4082 once daily (QD) or a dose-matched placebo to reach maintenance dose 4.
  • Experimental: Panel E: Dose Escalation to Dosage 5
    Participants receive escalating doses of oral MK-4082 once daily (QD) or a dose-matched placebo to reach maintenance dose 5.

Primary Outcome Measure

Number of Participants Who Experience an Adverse Event (AE) [ Time Frame: Up to approximately 98 Days ]

Locations (5)

FacilityCityStateZIPSite coordinators
Anaheim Clinical Trials ( Site 0005)AnaheimCalifornia92801-
ProSciento Inc. ( Site 0002)Chula VistaCalifornia91911-
QPS-MRA, LLC ( Site 0003)South MiamiFlorida33143-
Bio-Kinetic Clinical Applications, LLD dba QPS-MO ( Site 0004)SpringfieldMissouri65802-
Hassman Research Institute Marlton Site ( Site 0006)MarltonNew Jersey08053-

Find similar trials in Anaheim, CA

By research site
Anaheim Clinical Trials· Anaheim, CAProSciento Inc.· Chula Vista, CAQPS-MRA, LLC· South Miami, FLBio-Kinetic Clinical Applications, LLD dba QPS-MO· Springfield, MOHassman Research Institute Marlton Site· Marlton, NJ

Related Studies